Back

Risk and causes of hospital admission in patients with atrial fibrillation on treatment with oral anticoagulants

30 August 2024 (12:00 - 12:40)
Organised by: Logo
Congress Presentation Part of: Risk assessment and prognosis in atrial fibrillation Rhythm Control, Antiarrhythmic Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Arianna Pannunzio

Sapienza University of Rome, Rome (Italy)

5 More presentations in this session

Presentation thumbnail
Invasive haemodynamic assessment shows the obesity-HFpEF phenotype is common amongst patients with symptomatic AF
Doctor J. Ariyaratnam (Adelaide, AU)
Abstract Slides Video
Presentation thumbnail
The association of NT-proBNP levels in atrial fibrillation patients and 3-year risk of heart hospitalization and death
Doctor K. Szummer (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Ambulatory polygraphy as a screening tool for obstructive sleep apnea in combination with semi-continuous rhythm monitoring in patients with atrial fibrillation: a pilot study
Miss R. Onder (Hasselt, BE)
Abstract Slides Video
Presentation thumbnail
An external validation of DOAC score in patients with atrial fibrillation following transcatheter aortic valve replacement
Doctor Y. Harano (Gifu, JP)
Abstract Slides Video
Presentation thumbnail
Novel predictor of thrombosis after left atrial appendage closure -Neutrophil to Lymphocyte Ratio (NLR), platelet to LymPhocyte Ratio (PLR), and Lymphocyte to Monocyte Ratio (LMR)-.
Doctor S. Ryuzaki (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Risk assessment and prognosis in atrial fibrillation

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET
You may be interested in
thumbnail
Congress Session
Registries on atrial fibrillation and sudden death
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
Cardiovascular outcomes in hospitalized patients with atrial fibrillation. A one-year follow-up

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources